Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Andrea Caravati
Based on 1 article published since 2010
(Why 1 article?)
||||

Between 2010 and 2020, Andrea Caravati wrote the following article about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article The role of age in pancreatic intraductal papillary mucinous neoplasms of the pancreas: Same risk of death but different implications for management. 2018

Marchegiani, Giovanni / Andrianello, Stefano / Perri, Giampaolo / Pollini, Tommaso / Caravati, Andrea / Secchettin, Erica / Malleo, Giuseppe / Bassi, Claudio / Salvia, Roberto. ·Department of General and Pancreatic Surgery - The Pancreas Institute, University of Verona Hospital Trust, Italy. · Department of General and Pancreatic Surgery - The Pancreas Institute, University of Verona Hospital Trust, Italy. Electronic address: roberto.salvia@univr.it. ·Dig Liver Dis · Pubmed #29941281.

ABSTRACT: BACKGROUND: Current guidelines do not address the role of age in the management of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. AIM: To evaluate whether clinical features and risk for malignancy are affected by patient's age at diagnosis. METHODS: In total, 2189 IPMNs, both surgically resected or surveilled, were dichotomized according to a 50-year-old cutoff and compared in terms of pathological features, cumulative risk of developing high-risk stigmata (HRS), overall survival (OS) and disease-specific survival (DSS). RESULTS: Patients <50 years had more frequent abdominal pain (38.5 vs. 22.4%; p < 0.01) and acute pancreatitis (20.4 vs. 9.3%; p < 0.01) at presentation. Patients ≥50 years old had more multifocal IPMNs (50 vs. 36.9%; p < 0.01), HRS (8.5% vs. 4.3%; p = 0.04) and invasive IPMNs (26.6% vs. 17.3%; p = 0.03) when resected. Moreover, patients ≥50 years old had a significantly higher cumulative risk of developing HRS over time, and a significantly lower OS, but similar DSS when compared with those <50 years old. CONCLUSIONS: IPMNs diagnosed in older patients are more likely to progress to HRS despite the fact that cancer-related death is not affected by age. The follow-up schedule should not be adjusted according to age, but one should take into account that IPMNs in younger individuals have more time to progress toward malignancy.